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ABSTRACT
Objective A key challenge towards a successful 
COVID-19 vaccine uptake is vaccine hesitancy. We 
examine and provide novel insights on the key drivers and 
barriers towards COVID-19 vaccine uptake.
Design This study involved an anonymous cross- sectional 
online survey circulated across the UK in September 2020. 
The survey was designed to include several sections to 
collect demographic data and responses on (1) extent of 
agreement regarding various statements about COVID-19 
and vaccinations, (2) previous vaccination habits (eg, if 
they had previously declined vaccination) and (3) interest 
in participation in vaccine trials. Multinominal logistic 
models examined demographic factors that may impact 
vaccine uptake. We used principle component analysis 
and text mining to explore perception related to vaccine 
uptake.
Setting The survey was circulated through various media, 
including posts on social media networks (Facebook, 
Twitter, LinkedIn and Instagram), national radio, news 
articles, Clinical Research Network website and newsletter, 
and through 150 West Midlands general practices via a 
text messaging service.
Participants There were a total of 4884 respondents 
of which 9.44% were black, Asian and minority ethnic 
(BAME) group. The majority were women (n=3416, 69.9%) 
and of white ethnicity (n=4127, 84.5%).
Results Regarding respondents, overall, 3873 (79.3%) 
were interested in taking approved COVID-19 vaccines, 
while 677 (13.9%) were unsure, and 334 (6.8%) would 
not take a vaccine. Participants aged over 70 years 
old (OR=4.63) and the BAME community (OR=5.48) 
were more likely to take an approved vaccine. Smokers 
(OR=0.45) and respondents with no known illness 
(OR=0.70) were less likely to accept approved vaccines. 
The study identified 16 key reasons for not accepting 
approved vaccines, the most common (60%) being the 
possibility of the COVID-19 vaccine having side effects.
Conclusions This study provides an insight into 
focusing on specific populations to reduce vaccine 
hesitancy. This proves crucial in managing the COVID-19 
pandemic.
INTRODUCTION
COVID-19 is an infectious disease that is 
caused by the SARS- CoV-2, initially detected 
in Wuhan, China, in November 2019.1 The 
WHO declared the COVID-19 epidemic a 
Public Health Emergency of International 
Concern on 30 January 2020.2 This highly 
infectious disease has led to worldwide 
curfews and social distancing restrictions 
to prevent further spread of COVID-19.3 
Although social distancing measures have 
been identified as one of the primary tools 
to reduce the transmission of COVID-19,4 
this has led to insurmountable effects on 
the economy and the social and mental well- 
being of people’s health.5
There is little evidence to suggest that 
the spread of COVID-19 will stop naturally 
through population immunity, that is, ‘herd 
immunity’.6 Population immunity takes 
place when a sufficiently large proportion of 
immune individuals exists in a population. 
Strengths and limitations of this study
 ► This is the largest and first cross- sectional online 
survey in the UK that allows examination of the 
various factors influencing the uptake of a potential 
approved COVID-19 vaccine.
 ► This survey has allowed us to gain a deeper insight 
and a snapshot into the uptake of a COVID-19 vac-
cine, at a time prior to vaccine launch.
 ► This study was generally inclusive across all demo-
graphic groups, including age and ethnicity, with 
similar numbers to the UK population.
 ► The participant cohort could have benefitted from 
greater black, Asian and minority ethnic group di-
versity and representation.
 ► There is likely to be selection bias among the re-
spondents completing the survey, and it provides a 
snapshot of the views at the time of response.
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With an estimated 0.3%–1.3% infection fatality ratio, the 
cost of reaching population immunity through natural 
infection would be very high.7 Men, older individuals and 
those with comorbidities are disproportionately affected, 
with an infection fatality ratio as high as 3.3%.8 Addition-
ally, Public Health England revealed the death rate from 
COVID-19 in England to be four times higher for black 
people and three times higher for Asian people than for 
their white counterparts.9 Thus, an effective vaccine may 
offer the safest way to reach population immunity, partic-
ularly if immunity boosts are needed with virus variant 
formation or reinfections.6 The BioNTech–Pfizer vaccine 
has now been approved by the Medicines and Healthcare 
products Regulatory Agency, and on 8 December, the UK 
became the first country to roll out a national vaccination 
programme for COVID-19.10 Shortly following this, the 
Oxford–AstraZeneca vaccine was approved for use in the 
UK, while the Moderna vaccine has been mainly adminis-
tered in the USA.11
A further challenge for successful vaccine uptake, 
particularly with COVID-19, is vaccine hesitancy. Despite 
previous successful vaccines, there has been a greater 
shift of attention given to ‘vaccine hesitancy’, described 
as those people who have concerns about vaccine safety, 
efficacy or need.12 This can include those who are unsure 
about taking the vaccine and may have concerns or 
those who would refuse to take the vaccine. Obstacles 
to vaccination can include lack of trust towards public 
health authorities or government strategies and access 
to rumours and myths, particularly around safety. This is 
largely influenced by the media.13 Vaccine uptake rates 
can also vary across different communities and ethnicities, 
with significantly lower uptake rates in the black, Asian 
and minority ethnic (BAME) community.14 15 Further-
more, recently cited adverse outcomes in the ongoing 
trials could discourage the public from participating in a 
COVID-19 vaccine programme.
With the newly approved vaccines now being rolled out 
to the public, this study has explored the key drivers and 
barriers to COVID-19 vaccine uptake at this pivotal time. 
The insights from this study could be valuable in deliv-
ering, supporting and promoting adequate uptake for 
the population- wide vaccine programme in other coun-




This study involved a national anonymous cross- sectional 
online survey. The survey was created in English via 
Google forms. The survey was open from 4 September 
2020 to 9 October 2020. The survey was circulated across 
the UK through various media. These included posts 
on social media networks (Facebook, Twitter, LinkedIn 
and Instagram), national radio, news articles, Clinical 
Research Network West Midlands (CRN WM) website 
and newsletter and through 150 West Midlands general 
practices via a text messaging service. The social media 
networks were used to target the general population 
with multiple posts during the month of September. 
The radio and news articles were centred on targeting 
BAME- specific individuals who are notoriously known to 
be under- represented in studies. The general practices 
sent a generic text to all patients in their practice asking 
for participation with a link to access the survey. Those 
without a mobile phone or internet service were unable 
to participate in the survey.
The interview questions were collated, reviewed and 
refined internally by a group of researchers. This was 
followed by an external review and further refinement by 
the CRN WM Equality, Diversity and Inclusion Research 
Champions Group. Feedback from this group was used to 
modify questions prior to the survey going live.
The survey (online supplemental appendix A) was 
designed to include several sections to collect demo-
graphic data and responses on (1) extent of agreement 
regarding various statements about COVID-19 and vacci-
nations, (2) previous vaccination habits (eg, if they had 
previously declined vaccination) and (3) level of interest 
in participation in vaccine trials.
Patient and public involvement
Patient and public involvement was through review of our 
research questions by the CRN WM Equality, Diversity 
and Inclusion Research Champions Group. This consists 
of a group of volunteers made up of patients and public 
and user groups.
Ethical approval and patient consent
This study was approved by local approval processes by 
the CRN WM. No ethical- related issues were identified. 
The Health Research Authority decision tool also indi-
cated that there was not a need for National Health 
Service (NHS) Research Ethics Committee review (online 
supplemental appendix B). Participants were provided 
with information about the study and how the data were 
going to be disseminated in the initial page of the survey. 
This was an entirely anonymous survey with no identifi-
able material or information collected. No individual 
consent was obtained as the patients participated without 
providing any identifiable material. However, implied 
consent was taken as participants proceeded to complete 
the survey after reading what the survey was about and 
how the data were going to be used.
Statistical analysis
The statistical analysis was done in five phases. The first 
described the data of the participants of the COVID-19 
survey, including the various factors considered in the 
analysis. The second phase investigated the various 
factors influencing the respondents’ interest in approved 
vaccines. This analysis was done using a multinomial 
logistic regression model. The analysis was done on the 
overall data, considering various factors such as age, 
gender, ethnicity (BAME and non- BAME), diagnosed 
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health condition and qualification. Estimates were 
computed for the whole data by the combination of the 
gender, age group and ethnicity stratifications. The third 
phase compared the BAME and the non- BAME commu-
nity responses of the COVID-19 vaccine survey using 
independent sample t- test. The fourth examination anal-
ysed the ‘non- uptake’ group, consisting of those respon-
dents who either chose not to uptake approved vaccines 
or were unsure. The fifth phase of the statistical analysis 
examined the key reasons cited by the respondents for 
not being willing to take an approved COVID-19 vaccine. 
This analysis was done using natural language processing 
technique considering the reasons quoted by the respon-
dents. The key reasons cited were further analysed based 
on gender and ethnicity classifications. All analysis was 
carried out in STATA V.16.
RESULTS
The survey had 4884 respondents. We received complete 
responses for each section, as participants were not 
able to submit the survey without completing all of the 
parts. The majority were women (n=3416, 69.9%) and of 
white ethnicity (n=4127, 84.5%). There were 461 BAME 
respondents (9.4%), while 49 (1%) respondents chose 
not to disclose their ethnicity. Among the BAME commu-
nity, 258 (5.3%) respondents were Asian/Asian British–
Indian, and overall, only 67 (1.4%) respondents were 
black/African/Caribbean/black British. The majority 
of the respondents were non- university degree holders 
(n=1574, 32.2%), while there were 1780 (36.4%) univer-
sity undergraduate degree holders and 1010 (20.7%) 
postgraduate respondents. The age group 50–59 were the 
largest participant age group (1101 responses, 22.5%), 
with 552 (11.3%) responses from those aged 70 and 
above. Ninety- two percent (n=4495) of the respondents 
were non- smokers, and 39.9% (n=1949) of the respon-
dents stated diagnosed health issues. See table 1 for the 
full breakdown.
Overall, 3873 (79.3%) respondents were interested in 
taking approved vaccines, while 677 (13.86%) respon-
dents were unsure, and only 334 (6.9%) stated that they 
were not going to take the vaccine. Figure 1 presents 
the OR of the various factors that significantly influ-
ence interest in taking the approved COVID-19 vaccines. 
The results indicate that except for factors of ‘no health 
issues’ (OR=0.70) and ‘smokers’ (OR=0.45), the rest of 
the factors have OR >1. Among those respondents who 
declared their educational qualification, graduates were 
more likely to take the vaccine compared with the non- 
graduates (considered as the reference group). Similarly, 
of those respondents who declared their gender, men 
were more likely to take the approved vaccine. Respon-
dents belonging to the age groups 50–69 (OR=5.45) and 
70 and above (OR=4.63) were more likely to accept the 
approved COVID-19 vaccine compared with the respon-
dents below 50 years old, which is considered as the refer-
ence group. Among the ethnicity groups, it is evident 
that the BAME community was more likely to accept the 
COVID-19 vaccine (OR=5.48). Within the BAME commu-
nity, the South Asian ethnicity, that is, Indian, Pakistani 
and Bangladeshi, showed more interest towards uptake 
of the approved COVID-19 vaccine. The figure shows the 
reference categories against which the ORs have been 
estimated.
Table 2 reports the mean scores of the survey question-
naire. For the survey, a 5- point Likert Scale was used, that 
is, strongly disagree (1), disagree (2), neutral (3), agree 
(4) and strongly agree (5). The mean scores for all the 
questions are above three, and the SD was very low for the 
general questions on vaccine, such as ‘vaccines are safe’ 
and ‘vaccines keep you healthy’. However, for the ques-
tions specific on COVID-19, the SD was higher. This indi-
cates that even though the respondents tend to agree on 
the importance and necessity of the COVID-19 vaccine, 
the responses varied considerably more than the generic 
ones. There was a significant difference in the mean score 
of the responses between the BAME and the non- BAME 
community, with mean scores of the former significantly 
higher than that of the latter community, although SDs 
were lower. That the variation of the scores of the BAME 
community was higher than the non- BAME community 
could possibly indicate that perception of vaccines differs 
widely across the BAME community.
The reliability coefficient range of the questionnaire 
is 0.91 (value of Cronbach’s alpha). The latent variables 
were estimated using principal component analysis. For 
the questionnaire, the null hypothesis of Bartlett’s test 
of sphericity was rejected at 1% significance level (P 
value <0.01), stating that the variables are not orthog-
onal, that is, they are correlated. The Kaiser- Meyer- Olkin 
value is 0.89, indicating that the sampling is adequate. 
The findings show that the OR of impact of ‘perception 
of COVID-19 vaccine on overall health’ (OR=3.34) on 
uptake of approved COVID-19 vaccine is considerably 
higher than the impact of ‘perception of generic vaccine 
on overall health’ (OR=1, reference category).
In total, 1011 respondents (20.7%) were classified 
into the ‘non- uptake’ group; within this group, 334 
(33%) would choose not to take the approved vaccine 
(‘refusers’), and 677 (67%) respondents were ‘unsure’. 
The ‘unsure’ group was two times larger than the 
‘refusers’. In the ‘non- uptake’ group, women accounted 
for 75% (n=759), with 33.6% (n=340) reported to have 
diagnosed health issues. Smokers were at 8.3% (n=84). 
Among the qualification classifications in the ‘non- 
uptake’ group, university graduates accounted for 37.2% 
(n=376), followed by school graduates (29.6%, n=299) 
and postgraduates (18.9%, n=191). Respondents without 
formal qualifications only constituted 1.7% (n=17). Only 
5.3% (n=54) respondents in the ‘non- uptake’ group were 
of the age group 70 years old and above. Among the non- 
takers of vaccine, the BAME community accounted for 
15.6% (n=158), while 80.9% (n=818) belonged to the 
non- BAME community. Of those who would choose not 
to have the vaccine, 52.1% (n=641) indicated that they 
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have previously declined vaccinations. The details are 
reported in table 3.
The survey identified 16 reasons cited by the respon-
dents for not taking approved COVID-19 vaccines. The 
details are reported in table 4. Panel A provides the 
percentages for the not sure category, whereas Panel B 
reports the details of the not interested category. In both 
categories, ‘unless completely tested with no proven side 
effect’ was the reason with the greatest response (71% for 
Panel A and 54.2% for Panel B).
At the end of the survey, there was an opportunity for 
free text comments. Some free text comments regarding 
reasons for not taking the vaccine revolved around the 
idea of the BAME community being used as ‘guinea pigs’ 
for trials to verify vaccine results and mistrust around 
government strategies.
DISCUSSION
This is the largest UK- based population survey, exam-
ining the views surrounding COVID-19 vaccination and 
providing a focus on key factors to drive vaccination 
uptake. This survey allows us to compare the UK with 
other countries that have similarly gained perceptions and 
potential vaccine uptake through an online survey. China 
had the highest rate of perceived vaccine uptake, where 
91.3% would accept an approved and available COVID-19 
vaccination.16 A survey done across seven European coun-
tries found that 74% of participants would be willing to get 
vaccinated against COVID-1917—a similar finding to our 
results. A recent survey undertaken in the USA showed 
the lowest COVID-19 vaccine acceptance rate of 67% with 
men, older adults, Asians and college and/or graduate 
degree holders more accepting of the vaccine.18
Table 1 Description of the survey respondents for the whole sample
Respondents
Percentage 
(%) Respondents Percentage (%)
Interested in approved COVID-19 vaccine Gender
  Interested 3873 79.3   Woman 3416 69.9
  Not interested 334 6.8   Man 1426 29.2
  Unsure 677 13.9   Prefer not to say 42 0.9
Age group Ethnicity
  Under 18 7 0.1   Caucasian—English/Welsh/Scottish/
Northern Irish/British
4127 84.5
  18–29 525 10.7   Caucasian—Irish 49 1.0
  30–39 708 14.5   Caucasian—Gypsy or Irish Traveller 3 0.1
  40–49 1042 21.3   Caucasian—Roma 2 0.0
  50–59 1101 22.5   Caucasian—others 193 4.0
  60–69 914 18.7   Asian/Asian British—Indian 258 5.3
  70 and above 552 11.3   Asian/Asian British—Pakistani 30 0.6
  Prefer not to say 35 0.7   Asian/Asian British—Chinese 19 0.4
BAME community     Asian/Asian British—Bangladeshi 18 0.4
  Non- BAME 4374 89.6   Mixed/multiple ethnic groups 69 1.4
  BAME 461 9.4   Black/African/Caribbean/black 
British—African
67 1.4
  Prefer not to say 49 1.0   Prefer not to say 49 1.0
Qualification Smoker
  No formal 
qualifications
127 2.6   Smoker 386 7.9
  Up to A level 1574 32.2   Non- smoker 4495 92.0
  University degree 
(undergraduate)
1780 36.4   Prefer not to say 3 0.1
  Postgraduate 1010 20.7 Diagnosed health issue
  Prefer not to say 393 8.0   No diagnosed health issues 2935 60.1
      At least one diagnosed health issue 1949 39.9
Note: The table above reports the demographic insights of the respondents of the COVID-19 survey. There were 4884 respondents, and the 
table is based on the full data collected.
BAME, black, Asian and minority ethnic.
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This is also the first survey to focus specifically on the 
BAME population and other high- risk groups identi-
fied as the government’s priority for vaccination. The 
79.2% of participants willing to be vaccinated exceeds 
the threshold required for COVID-19 population immu-
nity, estimated to be 74% in Europe.17 It is important to 
overcome the barriers to vaccine uptake and to target the 
non- takers, known as the ‘non- uptake’ group, in order 
to ensure that the population immunity threshold is met 
across the population.
In late September, the UK government published 
interim advice on high- risk groups that will be priori-
tised with the COVID-19 vaccination programme.19 A 
combination of clinical risk stratification and an age- 
based approach was used in determining these groups, 
placing clinically vulnerable and over 70 age cohort as 
priority groups. Both of these groups, according to our 
findings, are more likely to uptake the approved vaccine. 
Several studies have found that groups over the age of 
55 are more willing to get vaccinated.17 In a UK survey 
done with older adults and patients with chronic respi-
ratory disease, 86% of respondents wanted to receive a 
COVID-19 vaccine.20 This may be due to the awareness 
that older adults with comorbidities are at greater risk of 
COVID-19 complications.
While the overall proportion of BAME participants was 
relatively low in our study, the BAME recruitment was 
greater than any other UK COVID-19 vaccination- based 
study thus far. Our results found that the BAME commu-
nity in general is more likely to accept approved vaccines 
when compared with the non- BAME community. This 
contrasts with previous literature suggesting generally 
poor vaccination uptake rates in the BAME community, 
such as for child and influenza vaccinations.14 There has 
also historically been racial disparities surrounding trust 
in vaccines, where the BAME community is less likely to 
trust pharmaceutical companies and government strate-
gies.21 A primary reason for a potential increase in uptake 
with the COVID-19 vaccine may be due to the dispropor-
tionate amount of COVID-19 deaths in the BAME popu-
lation with a third of these patients being admitted to the 
intensive care unit.11
However, examining the individual ethnic groups, 
there are clear disparities with potential uptake. Our 
results showed that the South Asian groups showed 
more interest towards uptake of the approved COVID-19 
vaccine. The South Asian population made up most of 
the BAME participation, and historically, these groups 
have a higher uptake in vaccination programmes in the 
UK and also in their home countries, where trust in the 
medical profession is high.18 22 Only 1.4% of our study 
participants were black British, making it difficult to fully 
deduct the views of this community with such a limited 
sample size. However, our findings support previous liter-
ature surrounding the black community and their lower 
vaccine uptake rates.23 There is a deep- rooted mistrust 
Figure 1 ORs showing factors influencing interest in taking an approved COVID-19 vaccine. BAME: black, Asian and minority 
ethnic.
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within this community in medical and vaccine research, 
due to historical oppression and health inequalities.20 24 
Several US studies have supported this, with the black 
community having higher levels of COVID-19 vaccine 
hesitancy.15 18 The perception surrounding vaccines 
differs widely across the BAME community and remains a 
challenge for this high- risk group.
Aside from ethnic differences, our study identified 
that smokers, those aged 40–49 and those with no known 
illness were less likely to accept approved vaccines. This 
is the first study to identify smokers being less likely 
to accept approved vaccines and could be an area of 
concern. Smokers are 1.4 times more likely to have severe 
symptoms of COVID-19 and approximately 2.4 times 
more likely to be admitted to an intensive care unit.25 A 
younger and healthy cohort being less willing to vaccinate 
has also been supported by study findings in Europe and 
the USA15 17 and may reflect the perception from these 
groups that they have less complications of COVID-19 or 
may die from it.26 However, with the infectious nature of 
COVID-19, having these groups not vaccinated poses a 
greater risk of spreading to those susceptible to greater 
complications from COVID-19.27
Contrary to previous studies,15 educational qualifi-
cations did not have an influence on vaccine uptake 
in our study. This may suggest that vaccination atti-
tude is more likely to be influenced by motivational 
and psychological factors, including a feeling of indi-
vidual responsibility for population- wide health, rather 
than education.27 The 52.1% of the non- takers had a 
recorded history of declined vaccination in the past, 
making it more likely that this is a long- term view held 
about vaccinations, with a similar trend found in other 
studies.15
Table 3 Non- uptakers of approved COVID-19 vaccine
Non- uptakers category
  Not sure (677 respondents) Refusers (334 respondents) Total (1011 respondents)
Gender (%)
  Man 20.38 26.05 22.26
  Woman 78.29 68.56 75.07
  Prefer not to say 1.33 5.39 2.67
  Smoker (%) 5.61 13.77 8.31
  Diagnosed health condition (%) 35.45 29.94 33.63
Qualification (%)
  No qualification 2.22 0.60 1.68
  School graduates 31.17 26.35 29.57
  Graduates 37.81 35.93 37.19
  Postgraduates 19.20 18.26 18.89
  Prefer not to say 9.60 18.86 12.66
Age group (%)
  Under 18 0.00 0.30 0.10
  18–29 13.00 15.87 13.95
  30–39 18.46 20.66 19.19
  40–49 23.63 26.95 24.73
  50–59 25.26 20.06 23.54
  60–69 11.67 8.98 10.78
  70+ 6.50 2.99 5.34
  Prefer not to say 1.48 4.19 2.37
Ethnicity (%)
  BAME 9.45 16.77 15.63
  Non- BAME 83.31 76.05 80.91
  Prefer not to say 7.24 7.19 3.46
  Record of declined vaccination 
(%)
20.53 52.09 30.95
Note: The table reports the demographic details of respondents who chose not to take the COVID-19 vaccine. Overall, 1011 respondents 
chose not to take the vaccine.
BAME, black, Asian and minority ethnic.
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Our study reports 16 key reasons for not accepting 
approved vaccines, with the main one being fear of side 
effects. Other studies have also identified safety as a key 
reason for vaccine hesitancy.15 20 At the time of the survey 
circulation, news channels were publicising the Oxford–
AstraZeneca trial being paused due to participants having 
side effects, and this was widely circulated in the media at 
the time.28 Specifically, there were concerns of side effects 
of transverse myelitis that, although may not be directly 
linked to the vaccine, could also not be ruled out.29 This 
could have influenced participants’ view on the safety of 
vaccines.
This survey was done at the time when an approved 
vaccine had not yet been made available. However, now 
that vaccines have been licensed and shown to be safe 
and effective, recent surveys have shown the intention 
to vaccinate is higher. Nguyen et al’s study showed that 
from September to December 2020, intent to receive 
COVID-19 vaccination increased by around 10% and 
non- intent decreased by 6%.30
Similar numbers from our ‘non- uptake’ group were 
found in another UK- based study.31 However, in our 
study, the ‘unsure’ group is twice the size of the ‘non- 
uptake’ group. An Australian study by Attwell et al32 
demonstrated that respondents were more likely to be in 
the ‘maybe’ group versus the ‘no’ group for vaccination if 
they perceived COVID-19 to be a severe disease and not a 
‘hoax’, were more likely to have the influenza vaccination 
and had greater trust in science. In the case of our study, 
the ‘unsure’ group, which makes a significant portion of 
the ‘non- uptake’ group, may change their mind about 
the vaccine once further details on an approved vaccine 
become available, particularly information on safety and 
efficacy. Furthermore, they may be more willing to take 
the vaccine if it is positively promoted on social media. 
This is reinforced by a repeat of Attwell et al’s survey in 
November 2020, compared with May 2020, that found 
more respondents being in the ‘maybe’ category for 
vaccination, conveying how dynamic and changing the 
decision making process can be.
The next most common reason (16.1%) was having an 
‘impaired immune system’. This would include patients 
who are on immunosuppressant medication or have 
a cancer diagnosis. However, similar to the influenza 
vaccine, those with an impaired immune system are 
still encouraged to have the annual influenza vaccina-
tion.33 The hesitancy in vaccine uptake in this immuno- 
compromised cohort may also be linked back to safety 
and the belief that vaccines may be suboptimal34 and 
ultimately whether the risks of taking the vaccine may 
outweigh the benefits. However, this may well sway the 
‘unsure’ group into the ‘uptake’ group as they see more 
people with various comorbidities taking the vaccine 
without any adverse effects.
Participants added their own reasons for not accepting 
approved vaccines. This revolved around the idea of the 
BAME community being used as ‘guinea pigs’ for trials 
to verify vaccine results and mistrust around government 
strategies, which has been supported in other studies.21 
These views may have also been influenced by social 
media views at the time, particularly those highlighting 
vaccines as being rushed and rolled out quickly to the 
public without adequate testing. Furthermore, in terms of 
the views surrounding vaccines in general compared with 
a COVID-19- specific one, there was more variety in the 
responses related to the COVID-19- specific statements 
compared with the generic vaccine ones, and this was 
particularly found in the BAME responses. The topical 
nature surrounding COVID-19 vaccinations specifically is 
likely to draw more polarised opinions, particularly given 
the constant focus on COVID-19 in social media and news 
channels. Twitter reported a COVID-19- related tweet 
every 45 milliseconds, and the hashtag #coronavirus is the 
second most used in 2020.35 There are also greater anti-
vaccination sentiments shared on social media compared 
with those promoting uptake, which can lead to consider-
able public health concerns and the consequent potential 
to downstream vaccine hesitancy.35
Interventional educational and public health campaigns 
need to be targeted towards populations at risk of vaccine 
hesitancy and challenge the key reasons for not accepting 
approved vaccines. Furthermore, policymakers and share-
holders need to be aware that these key reasons cited by 
the non- uptake cohort are potential barriers to vaccine 
uptake. This is to combat misinformation, particularly 
those circulated on social media platforms in an uncen-
sored manner.35 Our study also reveals that the percep-
tion of vaccine on one’s overall health plays a significant 
driver in the decision for uptake of an approved vaccine. 
There is an understanding in our population cohort that 
vaccines are important in the fight against COVID-19 
and that vaccines are needed to prevent COVID-19. This 
needs to be highlighted further in promotion and educa-
tion of vaccines.36
A limitation of this study is that, while this is one of 
the most BAME- inclusive COVID-19 vaccination- related 
studies, our BAME participant percentage (9.44%) is 
still below the overall BAME representation in the UK, 
which is approximately 14%.37 In particular, we received 
a very small amount of black and East Asian (eg, Chinese) 
participants, so it is difficult to fully deduct the views of 
the entirety of the BAME community. From the data that 
we have, however, it appears that the UK black commu-
nity follows a similar trend to the USA in higher levels 
of vaccine hesitancy, but this can be difficult to gener-
alise with such a small data set. Regardless, further work 
is needed to engage the black community in research 
participation and, from the limited data we do have, also 
in vaccine promotion.
Similar to other published surveys, there was also selec-
tion bias, as a computer or smart phone was needed to 
complete the survey. This may have excluded the older 
population, who is less likely to be digitally literate, and 
also economically marginalised groups. There are data 
suggesting these groups engage the least with the UK NHS 
digital resources, and it remains a challenge to provide 
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reliable and updated information to them.23 This survey 
is also more likely to attract responses from those who are 
motivated to complete this survey and who are more likely 
to have stronger opinions related to the COVID-19 vacci-
nation, attracting selection bias. Furthermore, there is a 
clear skew towards women and those more educated, so it 
may be difficult to generalise our results to the entire UK 
population. This survey also remains a snapshot of what 
the view was as of September 2020, but it may have likely 
changed since the vaccination programme has started or 
even in the early phases of the trials as other studies have 
suggested.30 32
Strengths of our study include the ability to stratify on 
demographic factors to predict COVID-19 vaccine uptake. 
Exploring key reasons towards vaccine hesitancy provides 
policymakers and key shareholders an insight into how to 
effectively target public health campaigns.
CONCLUSION
The uptake of approved vaccines is crucial in the fight 
against the COVID-19 pandemic. These novel findings 
regarding public insight on vaccines, including key 
barriers and facilitators towards vaccination, have the 
potential to shape future policy, practice and intervention 
development. This study provides necessary policy recom-
mendations essential for the UK government and the UK 
medical advisory team on designing strategies. This study 
emphasises policies targeting the needs of increased 
participation from the BAME community, young people 
and those with no diagnosed health conditions to uptake 
approved COVID-19 vaccines. This will allow the UK to 
effectively reach population immunity thresholds nation-
wide and in controlling further outbreaks of this rapidly 
spreading disease. Widespread vaccine uptake will be a 
crucial turning point in rebuilding the nation’s social, 
health and financial losses from this unprecedented 
pandemic.
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